Accelerating access to novel therapies for Asian patients with liver disease
At Hepalys Pharma, we are committed to improving the lives of patients in Japan and Asia through the development of innovative therapeutics for liver disease.
Accelerating access to novel therapies for Asian patients with liver disease
At Hepalys Pharma, we are committed to improving the lives of patients in Japan and Asia through the development of innovative therapeutics for liver disease.
Hepalys Pharma is a private, late-stage clinical biopharmaceutical company in Japan committed to the development of innovative therapeutics that address unmet needs in the management of liver disease for Japanese and Asian patients.
The Problem
While hepatitis treatments advance, gaps persist in liver diseases like MASH
Treatment options for viral hepatitis have markedly improved in recent years.
As those for non-viral liver diseases — such as metabolic dysfunction-associated steatohepatitis (MASH) — continue to highlight a persistent unmet medical need for patients and prescribers.
The prevalence of MASH is rising in parallel with increasing rates of obesity and lifestyle-related diseases.
Current treatment options for MASH in Japan remain limited, primarily consisting of dietary modifications, physical activity, and management of associated metabolic conditions.
MASH frequently results in cirrhosis and hepatocellular carcinoma (HCC).
The Solution
Hepalys Pharma was founded by Catalys Pacific to be a multi-asset biopharmaceutical company in Japan, focused on the needs of Japanese and Asian patients with liver disease.
To address the growing number of patients with MASH, Hepalys has initiated the clinical development of Lanifibranor.
Lanifibranor is a first-in-class therapeutic agent targeting pan-peroxisome proliferator-activated receptor (pan-PPAR), which regulates key metabolic, inflammatory, and fibrotic pathways implicated in the pathogenesis of MASH.
Lanifibranor demonstrated best-in-class efficacy in a Phase 2b study and is currently being evaluated for its potential to improve outcomes in patients with MASH in an ongoing global Phase 3 study.
Beyond Lanifibranor, Hepalys continues to identify high priority needs and potential solutions for patients with liver disease in Japan and Asia.
News
